参考文献/References:
[1]BRAY F,LAVERSANNE M,SUNG H,et al.Global cancer statistics 2022：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2024,74(3)：229-263.
[2]程逸风,张维康.结直肠癌合并急性肠梗阻的治疗策略[J].临床外科杂志,2024,32(5)：457-460.
[3]ROBERTS L M,BUFORD T W.Lipopolysaccharide binding protein is associated with CVD risk in older adults[J].Aging Clin Exp Res,2021,33(6)：1651-1658.
[4]袁翊,张春红,曹建,等.血清LBP、CXCL-10对小儿急性上呼吸道细菌感染的鉴别诊断价值及其影响因素[J].国际检验医学杂志,2024,45(6)：659-662,666.
[5]郭宇,刘颖,梁玉龙,等.新型生物标志物presepsin在临床感染性疾病诊疗中的应用与探讨[J].临床检验杂志,2022,40(2)：132-137.
[6]吴玉芹,黄荣卫,刘兴祝,等.NLR、LDH、IL-6在肺炎支原体肺炎患儿病情及预后评估中的价值[J].发育医学电子杂志,2024,12(4)：278-283.
[7]田辉,陈玉娥.血清C-反应蛋白和乳酸脱氢酶检测对急性肠梗阻患者治疗及预后评估的价值分析[J].当代临床医刊,2022,35(4)：79-80.
[8]中华人民共和国国家卫生健康委员会.中国结直肠癌诊疗规范（2020年版）[J].中华外科杂志,2020,58(8)：561-585.
[9]贾俊海,杨敬致,刘爱萍,等.肠梗阻临床实践指南方法学质量评价[J].中国医药导刊,2018,20(4)：193-198.
[10]刘宗超,李哲轩,张婧莹,等.2020全球癌症统计报告解读[J].肿瘤综合治疗电子杂志,2021,7(2)：1-14.
[11]周鹏飞,董晓琳,查名宝.清肠解毒方联合化疗治疗晚期结直肠癌疗效及对患者预后的影响[J].陕西中医,2024,45(9)：1226-1229.
[12]胡文婷,陈江,曹一波,等.复方苦参注射液联合化疗治疗结直肠癌的临床疗效及安全性的meta分析[J].空军军医大学学报,2024,45(3)：303-310.
[13]丁宗豪,汪泳,陈博.血清肠脂肪酸结合蛋白、碱性磷酸酶、D-二聚体在肠梗阻患者中的表达变化及临床价值研究[J].陕西医学杂志,2024,53(3)：340-343.
[14]OKUDA Y,SHIMURA T,YAMADA T.et al.Colorectal obstruction is a potential prognostic factor for stage Ⅱ colorectal cancer[J].Int J Clin Oncol,2018,23(6)：1101-1111.
[15]PARK B S,LEE J O.Recognition of lipopolysaccharide pattern by TLR4 complexes[J].Exp Mol Med,2013,45(12)：e66.
[16]YU Y,SONG G.Lipopolysaccharide-binding protein and bactericidal/permeability-increasing protein in lipid metabolism and cardiovascular diseases[J].Adv Exp Med Biol,2020,1276：27-35.
[17]张振宇,米传靓,李思迪,等.基于16S rRNA测序分析脂多糖结合蛋白基因敲除对小鼠肠道菌群的影响[J].中国医药生物技术,2023,18(2)：110-115.
[18]李蕾,李光浩,郑白冰,等.血浆外泌体脂多糖结合蛋白对结直肠癌早期诊断及进展监测价值分析[J].中华肿瘤防治杂志,2023,30(16)：964-971.
[19]PICCIONI A,SANTORO M C,DE C T,et al.Presepsin as early marker of sepsis in emergency department：A narrative review[J].Medicina (Kaunas),2021,29;57(8)：770.
[20]VELISSARIS D,ZAREIFOPOULOS N,KARAMOUZOS V,et al.Presepsin as a diagnostic and prognostic biomarker in sepsis[J].Cureus,2021,13(5)：e15019.
[21]王军锋,阴兆辉,王俊利,等.糖尿病足感染患者血清presepsin水平与感染程度的相关性[J].国际检验医学杂志,2024,45(2)：242-246.
[22]郝磊,徐云玲,郝坤.可溶性白细胞分化抗原CD14亚型、Toll样受体4诊断急性胰腺炎并发肾损伤的临床价值[J].临床外科杂志,2023,31(10)：931-935.
[23]刘虹伶,王美佳,晏青霞.多发性骨髓瘤患者血清β2-微球蛋白、肿瘤坏死因子-α、乳酸脱氢酶检测及临床意义[J].陕西医学杂志,2024,53(3)：399-402.
[24]GASSENMAIER M,LENDERS M M,FORSCHNER A,et al.Serum S100B and LDH at baseline and during therapy predict the outcome of metastatic melanoma patients treated with BRAF inhibitors[J].Target Oncol,2021,16(2)：197-205.
[25]MOU K,SHI M L,YANG F L,et al.Clinicopathological characteristics of patients with intestinal diffuse large B-cell lymphoma[J].Zhongguo Shi Yan Xue Ye Xue Za Zhi,2021,29(2)：508-514.
[26]刘悦,廖秀奇,明厚昉.术前CRP/ALB比值对结直肠癌术后肠梗阻的预测价值研究[J].现代医药卫生,2023,39(3)：394-398.
相似文献/References:
[1]柯东平,毛俊倩,刘 琪,等.TRIM21调控人结直肠癌细胞增殖分子机制研究*[J].陕西医学杂志,2019,(6):691.
KE Dongping,MAO Junqian,LIU Qi,et al.Study on molecular mechanisms of TRIM21 in regulating proliferation of colorectal cancer[J].,2019,(6):691.
[2]张 慧,陈景志,陈建立△,等.DCC和MKK4基因在结直肠癌组织中的表达及临床意义*[J].陕西医学杂志,2019,(8):968.
ZHANG Hui,CHEN Jingzhi,CHEN Jianli,et al.Expression and clinical significance of DDC and MKK4 genes in colorectal cancer tissue[J].,2019,(6):968.
[3]高怀军,余 伟.腹腔镜结直肠癌根治术治疗结直肠癌临床疗效及对患者胃肠功能的影响[J].陕西医学杂志,2019,(8):990.
GAO Huaijun,YU Wei..Clinical study of laparoscopic radical resection in the treatment of colorectal cancer in and its influence on gastrointestinal function[J].,2019,(6):990.
[4]赵英旋,白玉勤.结直肠癌患者肿瘤出芽情况与临床病理特征、程序性死亡受体1及程序性死亡配体1表达相关性研究[J].陕西医学杂志,2021,50(6):747.[doi:DOI:10.3969/j.issn.1000-7377.2021.06.027]
ZHAO Yingxuan,BAI Yuqin.Correlation between tumor budding and clinicopathological characteristics,expression of PD-1 and PD-L1 in CRC[J].,2021,50(6):747.[doi:DOI:10.3969/j.issn.1000-7377.2021.06.027]
[5]马 骞,朱 军,蔡梦珊,等.基于exoRBase外泌体数据库结直肠癌竞争性内源RNA网络构建及富集分析[J].陕西医学杂志,2021,50(7):797.[doi:DOI:10.3969/j.issn.1000-7377.2021.07.007]
MA Qian,ZHU Jun,CAI Mengshan,et al.Construction and enrichment analysis of competing endogenous RNA network for colorectal cancer based on the exoRBase database[J].,2021,50(6):797.[doi:DOI:10.3969/j.issn.1000-7377.2021.07.007]
[6]章玉玲,周 岳.结直肠癌患者血清循环肿瘤细胞、糖类抗原24-2、糖类抗原19-9水平及其与临床病理特征关系[J].陕西医学杂志,2022,51(3):322.[doi:DOI:10.3969/j.issn.1000-7377.2022.03.013]
ZHANG Yuling,ZHOU Yue.Serum circulating tumor cells,carbohydrate antigen 24-2 and carbohydrate antigen 19-9 levels in patients with colorectal cancer and their relationship with clinicopathological features[J].,2022,51(6):322.[doi:DOI:10.3969/j.issn.1000-7377.2022.03.013]
[7]张利伟,胡海燕.粪便硫酸类肝素蛋白多糖2与分泌型卷曲相关蛋白2基因甲基化检测在结直肠癌筛查中的应用价值[J].陕西医学杂志,2022,51(3):366.[doi:DOI:10.3969/j.issn.1000-7377.2022.03.024]
ZHANG Liwei,HU Haiyan.Application value of feces detection of syndecan-2 and secreted frizzled related protein 2 gene methylation in colorectal cancer screening[J].,2022,51(6):366.[doi:DOI:10.3969/j.issn.1000-7377.2022.03.024]
[8]曹巍巍,郭修田.结直肠癌原位移植造模技术研究进展[J].陕西医学杂志,2022,51(6):764.[doi:DOI:10.3969/j.issn.1000-7377.2022.06.029]
CAO Weiwei,GUO Xiutian.Research progress of orthotopic transplantation technology for colorectal cancer[J].,2022,51(6):764.[doi:DOI:10.3969/j.issn.1000-7377.2022.06.029]
[9]张言言,韩 刚,曹 羽,等.同源盒基因10调控胰岛素样生长因子结合蛋白3与肠癌细胞5-氟尿嘧啶抵抗的关系研究[J].陕西医学杂志,2022,51(7):771.[doi:DOI:10.3969/j.issn.1000-7377.2022.07.001]
ZHANG Yanyan,HAN Gang,CAO Yu,et al.Relationship between regulation of IGFBP3 by HOXD10 and 5-fluorouracil resistance in colorectal cancer cells[J].,2022,51(6):771.[doi:DOI:10.3969/j.issn.1000-7377.2022.07.001]
[10]张晓峰,冯 景,季飞燕,等.结直肠癌术后辅助化疗患者肠内营养不耐受影响因素及小野寺预后营养指数预测价值分析[J].陕西医学杂志,2022,51(9):1114.[doi:DOI:10.3969/j.issn.1000-7377.2022.09.016]